(Breast Cancer) Is Enhertu Effective for Brain Metastases?

On August 8, 2022, Dr. Rupert Bartsch and colleagues from the Medical University of Vienna published results in Nature Medicine from the TUXEDO-1 Phase 2 clinical trial evaluating the efficacy and safety of Enhertu (trastuzumab deruxtecan) in HER2-positive breast cancer patients with brain metastases.

The TUXEDO-1 Phase 2 trial administered Enhertu (5.4 mg/kg every 3 weeks) to patients with untreated or previously treated brain metastases from HER2-positive breast cancer (N=15). The primary endpoint was intracranial response rate.

Patient characteristics: 60% had brain metastases that progressed on prior treatment; 14 female and 1 male; median age 69 years (range: 30–76); ECOG PS 0 in 40%; 12 patients had hormone receptor-positive disease.

Results:

Primary endpoint intracranial response rate: 73.3% (N=11/15), comprising:

• Complete response: 13.3% (N=2)
• Partial response: 60% (N=9)
• Stable disease: 20% (N=3)

Median progression-free survival (PFS): 14 months.

Conclusion: Based on the TUXEDO-1 trial results, Dr. Bartsch and colleagues concluded that Enhertu demonstrated a high intracranial response rate in HER2-positive breast cancer patients with brain metastases.

Source: https://www.nature.com/articles/s41591-022-01935-8

Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).

Figure 1

Figure 2

Figure 3

Figure 4

Related Cancer Information

• Breast cancer